OCT 2 8 1999 A

RECEIVED 1500/2900

TECH CENTER 1500/2900

RECEIVED RECEIVED 1500/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 33 AM 8:34

In re application of

Jean PLOUET et al.

Serial No. 09/091,561

Filed August 21, 1998

ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF AS DRUGS GROUP 1646

Examiner L. Spect

11-3-99

## **AMENDMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the Official Action of September 28, 1999, please amend the above-identified application as follows:

## IN THE CLAIMS:

Replace all the claims now in the case with the following new claims:

--18. Method for diagnosis or treatment of pathologies involving endothelial cells engaged in an angiogenesis process, comprising administering an effective amount of an anti-idiotypic vascular endothelial growth factor antibody which is circulating, targets angiogenic endothelial cells and is a ligand of the human KDR receptor or of the murine flk-1 receptor, without affecting quiescent endothelial cells.

--19. Method according to claim 18 for treatment of pathologies involving endothelial cells engaged in an angiogenesis process, without affecting quiescent endothelial

 $\alpha_{l}$